secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2024-06-05T23:59:59+00:00
Accession:  0001576885-24-000067
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Acumen stockholders elect two Class III directors, ratify Ernst & Young as auditor for FY2024
--------------------------------------------------------------------------------

- Daniel O'Connell received 40,490,834 votes for, 48,338 withheld; Nathan Fountain 34,164,444 for, 6,371,549 withheld.
- Ratification of Ernst & Young as auditor: 52,367,645 for, 7,093 against, 6,271 abstained.
- Approximately 87% of outstanding shares (52,381,009 of 60,079,778) were present at the annual meeting.
- Directors elected to serve until the 2027 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000157688524000067/0001576885-24-000067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000157688524000067/abos-20240604.htm
  HTML page:      https://secwatch.observer/filing/0001576885-24-000067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer